Interius BioTherapeutics

Interius BioTherapeutics is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, developing in vivo CAR T cell gene therapies for cancer and autoimmune diseases. The company's platform engineers targeted, programmable lentiviral vectors that directly reprogram a patient's own T cells inside the body — eliminating the need for ex vivo cell manufacturing. Interius BioTherapeutics dosed its first patient in a clinical trial in late 2024, marking a milestone for in vivo CAR gene therapy. In August 2025, Kite (a Gilead Sciences company) announced plans to acquire Interius BioTherapeutics for approximately $350 million to advance its in vivo cell therapy pipeline.